Cortexin vs Pinealon
Comparison of Cortexin (Moderate evidence) and Pinealon (Low evidence).
Last updated: February 12, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Cortexin
Dossier overview
Pinealon
Dossier overview
Overview
Cortexin and Pinealon are both studied in the peptide research space.
Cortexin: A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions.
Pinealon: A synthetic tripeptide (Glu-Asp-Arg) developed by Russian researcher Vladimir Khavinson as a ‘peptide bioregulator’ claimed to support brain function.
Evidence Comparison
| Aspect | Cortexin | Pinealon |
|---|---|---|
| Evidence Level | Moderate | Low |
| Human Studies | 12 | 2 |
| Preclinical Studies | 16 | 13 |
| Total Sources | 28 | 15 |
Key Differences
| Aspect | Cortexin | Pinealon |
|---|---|---|
| Category | Cognitive | Cognitive |
| Evidence Strength | Moderate | Low |
| Total Sources | 28 | 15 |
| Human Studies | 12 | 2 |
Summary
- Cortexin: Moderate evidence with 28 total sources (12 human)
- Pinealon: Low evidence with 15 total sources (2 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.